Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CVac
- Development stage
- Phase 2
- Lead developer
- Immutep
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
CVac is an immunotherapeutic agent developed as a cancer vaccine, primarily for ovarian cancer. It uses an ex vivo dendritic cell priming technology involving a mannan fusion protein (MFP), where a fusion protein of MUC1 and Glutathione S-transferase is coupled to oxidized polymannose. Dendritic cells are collected from the patient via leukapheresis, exposed to the MUC1 antigen conjugated with mannan outside the body, and then reintroduced into the patient to stimulate an immune response against cancer cells overexpressing MUC1. CVac was developed by Prima BioMed in Australia and advanced through Phase II clinical studies between 2001 and 2015. Clinical development was discontinued after inconclusive results in ovarian cancer trials. CVac is not related to CureVac or its mRNA-based products despite similar naming conventions.
- Brand names
- CVac
- Other names
- Cancer Vaccine
02
Targets
pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on CVac.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CVac.